SCHEMBL396429

SCHEMBL396429

CCN(CC)C(C(N)=O)n1c(C)c(C(=O)O)c(C)c1C=C1C(=O)Nc2c(Nc3cccc(NC(=O)c4ccccc4)c3)cccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 5/20 0.40
▸ SIRT2 Q8IXJ6 2/20 0.38
▸ TLK2 Q86UE8 3/20 0.36
▸ PSD A5PKW4 1/20 0.36
▸ JAK3 P52333 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ FLT4 P35916 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ NTRK3 Q16288 2/20 0.35
▸ GSK3B P49841 3/20 0.34
▸ BRAF P15056 2/20 0.34
▸ APAF1 O14727 1/20 0.34
▸ MITF O75030 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397245 0.93 MAPK14 (0.37) NTRK1TLK2PSDJAK3KIT
SCHEMBL398145 0.90 RET (0.44) NTRK1KDRFLT3NTRK3ALDH1A1
SCHEMBL398243 0.88 TLK2 (0.48) NTRK1TLK2JAK3KITFLT4
SCHEMBL396850 0.88 NTRK1 (0.53) NTRK1TLK2KITFLT4KDR
SCHEMBL394525 0.86 FLT3 (0.51) NTRK1TLK2KITFLT4KDR
SCHEMBL399277 0.85 TLK2 (0.47) NTRK1TLK2JAK3GSK3BAURKA
SCHEMBL393970 0.85 NTRK1 (0.44) NTRK1TLK2KITFLT4KDR
SCHEMBL399058 0.85 FLT3 (0.48) NTRK1TLK2JAK3KITFLT4
SCHEMBL394471 0.85 NTRK1 (0.40) NTRK1SIRT2TLK2PSDJAK3
SCHEMBL395038 0.85 MAPK14 (0.38) NTRK1TLK2PSDJAK3KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback